Literature DB >> 18664847

Clinical application of multidetector row computed tomography in patient with breast cancer.

Doo Kyoung Kang1, Min Ji Kim, Yong Sik Jung, Hyunee Yim.   

Abstract

Although multidetector row computed tomography is not the primary method of evaluating breast cancer, it could be performed as an excellent alternative, especially in the presence of magnetic resonance contraindications. Moreover, computed tomography can still have an important role in evaluation of nodal status, thoracic invasion, and distant metastasis because of the large area covered in a single examination. Our experience together with literature indicates that multidetector row computed tomography is a powerful supplementary method for evaluation of patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664847     DOI: 10.1097/RCT.0b013e31815074ce

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  3 in total

1.  Predictive Value of Preoperative Multidetector-Row Computed Tomography for Axillary Lymph Nodes Metastasis in Patients With Breast Cancer.

Authors:  Chun-Fa Chen; Yu-Ling Zhang; Ze-Long Cai; Shu-Ming Sun; Xiao-Feng Lu; Hao-Yu Lin; Wei-Quan Liang; Ming-Heng Yuan
Journal:  Front Oncol       Date:  2019-01-08       Impact factor: 6.244

2.  Potential of the Non-Contrast-Enhanced Chest CT Radiomics to Distinguish Molecular Subtypes of Breast Cancer: A Retrospective Study.

Authors:  Fei Wang; Dandan Wang; Ye Xu; Huijie Jiang; Yang Liu; Jinfeng Zhang
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

3.  Evaluation of human epidermal growth factor receptor 2 status of breast cancer using preoperative multidetector computed tomography with deep learning and handcrafted radiomics features.

Authors:  Xiaojun Yang; Lei Wu; Ke Zhao; Weitao Ye; Weixiao Liu; Yingyi Wang; Jiao Li; Hanxiao Li; Xiaomei Huang; Wen Zhang; Yanqi Huang; Xin Chen; Su Yao; Zaiyi Liu; Changhong Liang
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.